secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2025-07-18T23:59:59+00:00
Accession:  0001005286-25-000097
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore Biomedical approves FY2026 bonus plan for executives with EBITDA, revenue targets
--------------------------------------------------------------------------------

- Board approved FY2026 cash bonus plan for CEO Paul Josephs (100% target), CFO Ryan Lake (60%), and CAO Thomas Salus (50%).
- Bonus weighted 80% to Adjusted EBITDA and development revenue; max payout 200% of target; no bonus if minimum EBITDA unmet.
- Individual performance goals and company business goals each weighted 10%.
- Salus receives 125% of any bonus earned per employment agreement; all bonuses subject to clawback policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528625000097/0001005286-25-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528625000097/lndc-20250715.htm
  HTML page:      https://secwatch.observer/filing/0001005286-25-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer